ANGPTL3 inactivation lowers LDL cholesterol, in contrast to statins and PCSK9 antagonists, independently of the classical LDL receptor-mediated pathway and thus represents a promising therapeutic approach for individuals with HoFH characterized by a complete absence of LDLR activity [32]: In HoFH patients, the drug at 15 mg/kg bodyweight has been shown to markedly reduce LDL cholesterol by 49% with simultaneous decreases in triglyceride levels up to 55% compared to baseline [34•]. This evidence concerns the gene ANGPTL3 and homozygous familial hypercholesterolemia.